November 2003
This chart may not adequately reflect the percentages of side effects in women due to the limited number of women in many studies of these drugs.
The colors underneath each drug heading below indicate the rough percentage of people reporting each side effect for each drug. See key at the bottom of each section.
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
APV = Amprenavir; ATV = Atazanavir; fosAPV = Fosamprenavir; IDV = Indinavir;
LPV = Lopinavir + RTV; NFV = Nelfinavir; RTV = Ritonavir;
SQV(hgc) = Saquinavir hard gel capsule; SQV(sgc) = Saquinavir soft gel capsule
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
DLV = Delavirdine; EFV = Efavirenz; NVP = Nevirapine
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
ABV=Abacavir; Combivir = AZT + 3TC; Trizivir = AZT + 3TC + ABV
FTC=Emtricitabine; TNV = Tenofovir
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
T20 = Enfuvirtide
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |
| Reported in > 15% of people in clinical studies | Reported in 5–15% of people in clinical studies | Reported in < 5% of people in clinical studies | |||
| (blank) | Side effect has not been reported | C | Reported only in children, or more commonly in children | ‡ | Potentially fatal side effect |